AZD6765 single and multiple ascending dose study in healthy male and female Japanese and Caucasian subjects - JSAD/JMAD
Study identifier:D6702C00013
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Single-center, Randomized, Double-blind, Placebo-controlled Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6765 in Healthy Male and Female Japanese and Caucasian Subjects
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD6765, Placebo
Sex
All
Actual Enrollment
40
Study type
Interventional
Age
20 Years - 45 Years
Date
Study Start Date: 01 Nov 2008
Primary Completion Date: 01 Mar 2009
Study Completion Date: 01 Mar 2009
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Oct 2014 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: AZD6765 single administration and once daily for 5 days |
| Placebo Comparator: 2 given (2 subjects in each ethnic/dose group) | Drug: Placebo single administration and once daily for 5 days |
Contacts
Investigators
Principal Investigator
Mark Yen
California Clinical Trials
